Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706645 | 1.00 | ALDH1A1 (0.59) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1GRM5 | |
| SCHEMBL18706664 | 0.81 | HPGD (0.55) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1GRM5 | |
| SCHEMBL18706661 | 0.81 | HPGD (0.55) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1GRM5 | |
| SCHEMBL18707033 | 0.81 | GRM5 (0.45) | ALDH1A1GRM5NPC1HPGDKEAP1 | |
| SCHEMBL18707031 | 0.81 | GRM5 (0.45) | ALDH1A1GRM5NPC1HPGDKEAP1 | |
| SCHEMBL7589116 | 0.79 | ALDH1A1 (0.92) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1HSD17B10 | |
| SCHEMBL5909274 | 0.78 | ALDH1A1 (0.70) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1GRM5 | |
| SCHEMBL7585371 | 0.78 | ALDH1A1 (0.65) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1HSD17B10 | |
| SCHEMBL7588046 | 0.77 | ALDH1A1 (0.71) | ALDH1A1L3MBTL4L3MBTL3L3MBTL1HSD17B10 | |
| SCHEMBL4515095 | 0.75 | GRM5 (0.58) | GRM5KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060854-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | ALDH1A1 372/4885L3MBTL4 4193/4885L3MBTL3 3482/4885 |
| US-20180282349-A1 | BIARYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | ALDH1A1 372/4885L3MBTL4 4193/4885L3MBTL3 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.